8 completed, 3 terminated, 1 active not recruiting, 1 recruiting. 4 Phase 1, 3 Phase 2, 3 Phase 3, 1 Early Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Unknown 1 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Phase 3 | 3 | Terminated 2, Active not recruiting 1 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Hemophilia B with Inhibitor: new trials by email Literature Review of Hemophilia B with Inhibitor trials Research Report on Hemophilia B with Inhibitor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial SerpinPC - Hemophilia a, Hemophilia B | Phase 3 | Terminated | ApcinteX Ltd | 15 | 2024-07-11 | 2025-02-10 |
| Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors KN057 - Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | Phase 3 | Active not recruiting | Suzhou Alphamab Co., Ltd. | 53 | 2024-01-09 | 2025-09-17 |
| SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment SS109 - Male, Hemophilia A With Inhibitor | Phase 1 / Phase 2 | Completed | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 24 | 2023-10-12 | 2024-07-19 |
| A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors SerpinPC - Hemophilia B with Inhibitor, Hemophilia B | Phase 2 | Terminated | ApcinteX Ltd | 3 | 2023-07-28 | 2025-03-11 |
| A Phase I of SS109 in Hemophilia A or and B With Inhibitors SS109 - Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | Phase 1 | Completed | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 27 | 2022-12-14 | 2023-08-22 |
| SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors coagulation factor VIIa [recombinant]-jncw - Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | Phase 4 | Recruiting | American Thrombosis and Hemostasis Network | 55 | 2021-06-28 | 2026-01-12 |
| Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B MarzAA - Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | Phase 3 | Terminated | Catalyst Biosciences | 18 | 2021-05-04 | 2021-12-17 |
| Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors Eptacog alfa, activated - Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | Early Phase 1 | Completed | AryoGen Pharmed Co. | 14 | 2020-12-29 | 2022-09-10 |
| Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia. TQG203, TQG203/NovoSeven® - Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 24 | 2020-12-01 | 2021-02-24 |
| Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia MarzAA (marzeptacog alfa [activated]) - Hemophilia A, Hemophilia B | Phase 1 | Completed | Catalyst Biosciences | 11 | 2019-09-24 | 2021-09-13 |
| ATHN 7: Hemophilia Natural History Study Hemophilia A With Inhibitor, Haemophilia A Without Inhibitor | Completed | American Thrombosis and Hemostasis Network | 395 | 2018-10-24 | 2025-02-12 | |
| ATHN 8: Previously Untreated Patients (PUPs) Matter Study Hemophilia, Hemophilia A | Completed | American Thrombosis and Hemostasis Network | 237 | 2018-10-03 | 2023-02-01 | |
| Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B Coagulation Factor VIIa variant - Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | Phase 2 | Completed | Catalyst Biosciences | 11 | 2017-12-18 | 2021-09-23 |
| Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | Completed | AryoGen Pharmed Co. | 200 | 2016-06-13 | 2022-02-15 |
Hemophilia A (7) · Hemophilia B (5) · Factor VII Deficiency (2) · Thrombasthenia (1)
Blood Coagulation Disorders (9) · Blood Coagulation Disorders, Inherited (9) · Coagulation Protein Disorders (9) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9) · Genetic Diseases, Inborn (9) · Hematologic Diseases (9) · Hemic and Lymphatic Diseases (9) · Hemorrhagic Disorders (9) · Genetic Diseases, X-Linked (5) · Blood Platelet Disorders (1)
Protein C (2) · Factor VII (1) · Factor VIIa (1) · marzeptacog alfa (activated) (1) · recombinant FVIIa (1)
American Thrombosis and Hemostasis Network (3) · Catalyst Biosciences (3) · ApcinteX Ltd (2) · AryoGen Pharmed Co. (2) · Hangzhou Gensciences Biopharmaceutical Co., Ltd. (2) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Suzhou Alphamab Co., Ltd. (1)
United States (5) · China (4) · Armenia (3) · Georgia (3) · Russia (3) · India (2) · Iran (2) · Italy (2) · Poland (2) · South Africa (2) · Spain (2) · Taiwan (2) · Turkey (Türkiye) (2) · United Kingdom (2) · Australia (1)
Howard Levy, MD, PhD, MMM (2) · Changcheng Zheng, Doctor (1) · Chenghao Jin, Doctor (1) · Courtney Thornburg, MD, MS (1) · Hu Zhou, Doctor (1) · Jing Sun, Doctor (1) · Jingyu Yan, Doctor (1) · Lili Chen, Doctor (1) · Marijke van den Berg, MD, PhD (1) · Mark Reding, MD (1) · Massimo Iacobelli, MD (1) · Michael Recht, MD, PhD (1) · Mohammad Faranoush, MD (1) · Renchi Yang (1) · Renchi Yang, Doctor (1)
2023 (1)